Related Experiment Video
Updated: Jul 1, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
97
Novel therapeutic targets in dermatomyositis
Christina Bax1, Carmel Aghdasi1, David Fiorentino1
1Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA.
The Journal of Dermatology
|March 4, 2024
Summary
Dermatomyositis treatments are evolving beyond broad immunosuppression. New therapies target specific immune pathways and cells, aiming for better efficacy and fewer side effects in autoimmune disease management.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Dermatomyositis (DM) is a systemic autoimmune disease affecting skin, muscles, lungs, and joints.
- Current treatments rely on broad immunosuppression, which has limited effectiveness and significant side effects like infection risk.
- There is a critical need for improved, well-tolerated therapies for DM.
Purpose of the Study:
- To review emerging and planned therapeutic strategies for dermatomyositis.
- To highlight novel drug development targeting various immunological pathways in DM.
Main Methods:
- Literature review of ongoing and planned clinical trials for DM therapies.
- Analysis of therapeutic targets including immune cells and signaling pathways.
Main Results:
- Multiple new therapeutic strategies are under investigation for DM.
- These therapies target a diverse range of immunological components such as T cells, B cells, and type I interferons.
- Novel approaches also focus on autoantibodies and other specific immune mediators.
Conclusions:
- The pharmaceutical landscape for dermatomyositis is expanding with innovative treatments.
- These new therapies offer potential for more targeted and effective management of DM.
- Future treatments aim to improve patient outcomes by addressing unmet therapeutic needs.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K